Kyowa Kirin Management

Management criteria checks 3/4

Kyowa Kirin's CEO is Masashi Miyamoto, appointed in Mar 2018, has a tenure of 6.42 years. total yearly compensation is ¥157.00M, comprised of 52.9% salary and 47.1% bonuses, including company stock and options. directly owns 0.018% of the company’s shares, worth ¥294.34M. The average tenure of the management team and the board of directors is 3 years and 2.9 years respectively.

Key information

Masashi Miyamoto

Chief executive officer

JP¥157.0m

Total compensation

CEO salary percentage	52.9%
CEO tenure	6.4yrs
CEO ownership	0.02%
Management average tenure	3yrs
Board average tenure	2.9yrs

Recent management updates

Recent updates

Kyowa Kirin Co., Ltd. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Aug 03

Earnings Miss: Kyowa Kirin Co., Ltd. Missed EPS By 5.6% And Analysts Are Revising Their Forecasts

May 09

Kyowa Kirin (TSE:4151) Is Due To Pay A Dividend Of ¥29.00

Apr 25

Kyowa Kirin's (TSE:4151) Dividend Will Be ¥29.00

Apr 11

Here's Why We Think Kyowa Kirin (TSE:4151) Is Well Worth Watching

Mar 19

Kyowa Kirin Co., Ltd.'s (TSE:4151) 26% Price Boost Is Out Of Tune With Earnings

Feb 27

CEO Compensation Analysis

How has Masashi Miyamoto's remuneration changed compared to Kyowa Kirin's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	n/a	n/a	JP¥97b
Mar 31 2024	n/a	n/a	JP¥83b
Dec 31 2023	JP¥157m	JP¥83m	JP¥81b
Sep 30 2023	n/a	n/a	JP¥58b
Jun 30 2023	n/a	n/a	JP¥40b
Mar 31 2023	n/a	n/a	JP¥50b
Dec 31 2022	JP¥182m	JP¥83m	JP¥54b

Compensation vs Market: Masashi's total compensation ($USD1.07M) is below average for companies of similar size in the JP market ($USD1.73M).

Compensation vs Earnings: Masashi's compensation has been consistent with company performance over the past year.

CEO

Masashi Miyamoto (65 yo)

6.4yrs

Tenure

JP¥157,000,000

Compensation

Mr. Masashi Miyamoto Ph D., serves as Representative Director at Kyowa Kirin Co., Ltd. He serves as President of Kyowa Hakko Kirin Co., Ltd since March 2018, served as a Chief Operating Officer since March...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Masashi Miyamoto	President	6.4yrs	JP¥157.00m	0.018% ¥ 294.3m
Motohiko Kawaguchi	CFO & Managing Executive Officer	no data	no data	no data
Yutaka Osawa	CCO, Executive VP & Representative Director	2.6yrs	JP¥105.00m	0.013% ¥ 205.8m
Kazuki Nemoto	Head of Global Legal	1.3yrs	no data	no data
Hiroki Nakamura	Global Corporate Communications Head	no data	no data	no data
Hiroshi Sonekawa	Managing Executive Officer	3.4yrs	no data	no data
Takeyoshi Yamashita	Chief Medical Officer	3.6yrs	no data	0.0052% ¥ 83.2m
Yasuo Fujii	Chief Strategy Officer	6.6yrs	no data	no data
Jean-David Rafizadeh-Kabe	Head of Global Operational Transformation	2.6yrs	no data	no data
Yoshifumi Torii	Executive Officer & Head of Global Research	no data	no data	no data
Hiroki Takamatsu	VP, Head of Quality Assurance Division & Executive Officer	no data	no data	no data
Tomohiro Sudo	Executive Officer & Head of Global Product strategy	2.6yrs	no data	no data

3.0yrs

Average Tenure

65yo

Average Age

Experienced Management: 4151's management team is considered experienced (3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Masashi Miyamoto	President	13.3yrs	JP¥157.00m	0.018% ¥ 294.3m
Yutaka Osawa	CCO, Executive VP & Representative Director	6.4yrs	JP¥105.00m	0.013% ¥ 205.8m
Takeyoshi Yamashita	Chief Medical Officer	1.4yrs	no data	0.0052% ¥ 83.2m
Yoshihisa Q. Suzuki	Independent Outside Director	2.4yrs	no data	0.00025% ¥ 4.0m
Hiroshi Komatsu	Full-time Audit & Supervisory Board Member	6.4yrs	no data	0.00085% ¥ 13.7m
Akira Morita	Outside Independent Chairman	5.4yrs	no data	0.00066% ¥ 10.6m
Yuko Haga	Independent Outside Director	5.4yrs	no data	0.00085% ¥ 13.7m
Mayumi Tamura	Outside Audit & Supervisory Board Member	2.4yrs	no data	0.00011% ¥ 1.8m
Takashi Oyamada	Independent Outside Director	3.4yrs	no data	0.00059% ¥ 9.5m
Shinjiro Akieda	Director	less than a year	no data	no data
Rumiko Nakata	Independent Outside Director	1.4yrs	no data	0.000040% ¥ 643.7k
Toru Ishikura	Audit & Supervisory Board Member	1.4yrs	no data	no data

2.9yrs

Average Tenure

65yo

Average Age

Experienced Board: 4151's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.

Kyowa Kirin Management

Management criteria checks 3/4

Key information

Recent management updates

Kyowa Kirin Co., Ltd., Annual General Meeting, Mar 22, 2024

High number of new directors

Kyowa Kirin Co., Ltd., Annual General Meeting, Mar 24, 2023

High number of new directors

High number of new directors

High number of new directors

Recent updates

Kyowa Kirin Co., Ltd. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Kyowa Kirin Co., Ltd. Updates Earnings Guidance for He Fiscal Year 2024

Here's Why Kyowa Kirin (TSE:4151) Has Caught The Eye Of Investors

Kyowa Kirin Co., Ltd.'s (TSE:4151) Share Price Could Signal Some Risk

Kyowa Kirin (TSE:4151) Is Due To Pay A Dividend Of ¥29.00

Are Investors Undervaluing Kyowa Kirin Co., Ltd. (TSE:4151) By 35%?

Kyowa Kirin Co., Ltd. to Report Fiscal Year 2024 Results on Feb 06, 2025

Earnings Miss: Kyowa Kirin Co., Ltd. Missed EPS By 5.6% And Analysts Are Revising Their Forecasts

First quarter 2024 earnings: EPS misses analyst expectations

Kyowa Kirin (TSE:4151) Is Due To Pay A Dividend Of ¥29.00

Kyowa Kirin's (TSE:4151) Dividend Will Be ¥29.00

Final dividend of JP¥29.00 announced

Here's Why We Think Kyowa Kirin (TSE:4151) Is Well Worth Watching

Kyowa Kirin Co., Ltd. to Present Phase 2B Post-Hoc Analysis and Symposium At the American Academy of Dermatology Annual Meeting 2024

Kyowa Kirin Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Kyowa Kirin Co., Ltd.'s (TSE:4151) 26% Price Boost Is Out Of Tune With Earnings

Full year 2023 earnings: EPS and revenues exceed analyst expectations

New minor risk - Share price stability

Investor sentiment improves as stock rises 17%

Kyowa Kirin Co., Ltd. Declares Dividend for the Fiscal Year Ended December 31, 2023, Payable on March 25, 2024; Provides Dividend Guidance for the Second Quarter of 2024

Kyowa Kirin Co., Ltd., Annual General Meeting, Mar 22, 2024

Kyowa Kirin Announces First Patient Enrolled in the Phase 2 Clinical Trial Evaluating Tivozanib Eye Drops in Patients with Diabetic Macular Edema

Kyowa Kirin Co., Ltd. (TSE:4151) completed the acquisition of Orchard Therapeutics plc (NasdaqCM:ORTX) from RA Capital Management, L.P., Deep Track Capital, LP, Zentree Investment Management Pte. Ltd. and others.

Kyowa Kirin Co., Ltd. (TSE:4151) completed the acquisition of Orchard Therapeutics plc (NasdaqCM:ORTX) from RA Capital Management, L.P., Deep Track Capital, LP, Zentree Investment Management Pte. Ltd. and others.

Kyowa Kirin Co., Ltd. to Report Fiscal Year 2023 Results on Feb 07, 2024

Upcoming dividend of JP¥27.00 per share at 2.3% yield

Now 20% undervalued after recent price drop

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Kyowa Kirin Co., Ltd. (TSE:4151) entered into a Transaction Agreement to acquire Orchard Therapeutics plc (NasdaqCM:ORTX) from RA Capital Management, L.P., Deep Track Capital, LP, Zentree Investment Management Pte. Ltd. and others for approximately $470 million.

Kyowa Kirin Co., Ltd. to Report Q3, 2023 Results on Nov 01, 2023

New minor risk - Earnings quality

New minor risk - Profit margin trend

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Now 22% undervalued after recent price drop

Now 20% undervalued after recent price drop

Upcoming dividend of JP¥27.00 per share at 2.0% yield

Kyowa Kirin Co., Ltd. to Report Q1, 2024 Results on Aug 03, 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Kyowa Kirin Co., Ltd. Provides Dividend Guidance for the Year Ending December 31, 2023

High number of new directors

Full year 2022 earnings: EPS misses analyst expectations

Kyowa Kirin Co., Ltd., Annual General Meeting, Mar 24, 2023

Kyowa Kirin Co., Ltd. Declares Dividend for the Fiscal Year Ended December 31, 2022, Payable on March 27, 2023; Provides Dividend Guidance for the Second Quarter of 2023

Kyowa Kirin Co., Ltd. to Report Fiscal Year 2022 Results on Feb 07, 2023

Upcoming dividend of JP¥24.00 per share

Consensus forecasts updated

Kyowa Kirin Co., Ltd. Revises Consolidated Earnings Guidance for the Year Ended December 31, 2022

Kyowa Kirin Co., Ltd. and MEI Pharma, Inc. Announce Topline Data from Phase 2 MIRAGE Study Evaluating Zandelisib in Patients with Indolent B-Cell Non-Hodgkin’s Lymphoma in Japan

High number of new directors

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Kyowa Kirin Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending December 31, 2022

Kyowa Kirin Co., Ltd. Receives European Commission Approval for Use of CRYSVITA(R) (burosumab) for the Treatment of Tumour-Induced Osteomalacia

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Kyowa Kirin Co., Ltd. Announces Second Quarter End Dividend for the Fiscal Year Ending December 31, 2022, Payable from September 1, 2022; Provided Year End Dividend Guidance for the Fiscal Year Ending December 31, 2022

MEI Pharma and Kyowa Kirin Announce Publication in the Lancet Oncology of Data from Phase 1B Clinical Study of Zandelisib in Patients with Relapsed or Refractory B-Cell Malignancy

Kyowa Kirin Receives Positive CHMP Opinion for Use of CRYSVITA (burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO)

Upcoming dividend of JP¥24.00 per share

MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022

MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022

Kyowa Kirin Co., Ltd. Provides Dividend Guidance for the Second Quarter and Full Year Ending December 31, 2022

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

High number of new directors

High number of new directors

Now 20% undervalued after recent price drop

Kyowa Kirin Co., Ltd., Annual General Meeting, Mar 25, 2022

Full year 2021 earnings: EPS exceeds analyst expectations

Upcoming dividend of JP¥23.00 per share

MEI Pharma, Inc. and Kyowa Kirin Co., Ltd. Announce Data from Ongoing Global Phase 2 TIDAL Study Evaluating Zandelisib as Single Agent in Patients with Relapsed or Refractory Follicular Lymphoma